The intelligence of machines and the branch of computer science which aims to create it

Artificial Intelligence Journal

Subscribe to Artificial Intelligence Journal: eMailAlertsEmail Alerts newslettersWeekly Newsletters
Get Artificial Intelligence Journal: homepageHomepage mobileMobile rssRSS facebookFacebook twitterTwitter linkedinLinkedIn


Artificial Intelligence Authors: Pat Romanski, Progress Blog, William Schmarzo, Liz McMillan, SmartBear Blog

News Feed Item

HemoShear and Children's National Health System to Unveil New Paradigm for Accelerating Rare Disease Drug Discovery

~ Presentation Featured at Partnering for Cures Conference

CHARLOTTESVILLE, Va., Nov. 17, 2014 /PRNewswire/ -- HemoShear and Children's National Health System (CNHS) together will present at the 6th annual Partnering for Cures conference to be held November 16-18, 2014 in New York City. Marshall Summar, MD, Division Chief of Genetics and Metabolism at CNHS, and Brian Wamhoff, PhD, Vice President of R&D and Co-founder of HemoShear, will introduce a new paradigm for enabling discovery of new rare disease treatments in less time and with higher success rates.

Drs. Summar and Wamhoff will describe how Children's knowledge of disease genetics and access to patients, in combination with HemoShear's translational rare disease tissue systems, have the potential to uncover the biology of liver-focused rare diseases and to predict patient responses to new drug candidates. This new paradigm is a major advancement over traditional drug R&D approaches, such as animal models, because they do not mimic human rare disease biology, leading to high failure rates and high costs for very small patient populations.

"At Children's National, we treat more patients with rare diseases than nearly anywhere else in the world," said Dr. Summar. "Because we have few or no available drug therapies for most of the 7,000 rare genetic conditions, we are forced to treat the patients symptomatically, day to day, without addressing the underlying problem. For our metabolic rare disease patients, there simply are few reliable drugs. For many, a liver transplant is often the last therapeutic alternative. Even then our patients' lifespans can be tragically short."

"Our ability to accurately recreate liver rare diseases will be a major step forward in accelerating discovery and development of new treatments," said Dr. Wamhoff. "With the HemoShear platform, we expect to be able to unmask meaningful mechanisms behind these diseases, identify new targets and new drug candidates, and accelerate translation of optimal candidates into the clinic for children in need."

"The presentations at Partnering for Cures will address some of the thorniest issues in medical research using models that can be scaled and translated across diseases," said FasterCures' Executive Director Margaret Anderson. "From re-imagining clinical trial infrastructure to improving and expanding data sharing, to creating the tools and resources needed to translate basic science into cures, they are accelerating the path from lab to market for novel – and needed – therapies."

Drs. Summar and Wamhoff will present the Rare Disease Drug Discovery Accelerator at the conference on Tuesday, November 18 at 9:00 am. Their presentation is one of only thirty innovative approaches selected from 120 submissions.

Partnering for Cures is convened by FasterCures and the Milken Institute. More than 1,000 healthcare leaders, policy makers, investors and medical researchers will come together at the conference to share creative approaches to speed scientific discoveries and new therapies to patients. For more information about the conference, go to http://www.partneringforcures.org.

###

About Children's National Health System
Children's National Health System, based in Washington, DC, has been serving the nation's children since 1870. Children's National is Magnet® designated, and is consistently ranked among the top pediatric hospitals by U.S.News & World Report. Home to the Children's Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National is one of the nation's top NIH-funded pediatric institutions. With a community-based pediatric network, seven regional outpatient centers, an ambulatory surgery center, two emergency rooms, an acute care hospital, and collaborations throughout the region, Children's National is recognized for its expertise and innovation in pediatric care and as an advocate for all children. For more information, visit ChildrensNational.org, or follow us on Facebook and Twitter.

About the Division of Genetics and Metabolism at Children's National
The Division of Genetics and Metabolism at Children's National Health System is a hub for patients with rare and complex diseases, featuring an integrated team providing both diagnosis and treatment. The team at Children's National combines outstanding clinical care, cutting edge research and comprehensive diagnostics to improve the lives of their patients.

About HemoShear
HemoShear is a biotechnology company that is changing the way drugs are discovered and developed, departing from traditional scientific methods in favor of translational tissue systems that accurately replicate human disease biology. HemoShear works in strategic collaboration with pharmaceutical and biotechnology companies to discover new drugs across a wide range of diseases. Its transformational drug discovery platform integrates best-in-class human disease systems, a comprehensive biorepository, molecular and disease biology expertise, and cutting-edge computational biology. Together, they provide a unique and powerful lens to interpret biological mechanisms and human disease at a level not possible until now. Through its pioneering science, HemoShear's mission is to profoundly impact human health. THINK HUMAN.

SOURCE HemoShear

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.